Navigation Links
Sangart, Inc. Completes Series F Funding Round

SAN DIEGO, March 12 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of oxygen therapeutics, today announced the receipt of approximately $50 million in funding from existing investors. This investment results from the exercise of warrants issued by Sangart as part of a Series F financing round initiated in 2007. The most recent investment brings the total funding under the Series F round to approximately $100 million. Proceeds from this warrant exercise will be used to fund further clinical development of Sangart's MP4 oxygen therapeutic products.

"We are excited to see this continued support from our investors and believe it demonstrates the potential of our products," said Brian O'Callaghan, President and CEO of Sangart. "This funding contributes significantly to our efforts to further the clinical research and development of our MP4 oxygen therapeutic products."

About MP4 Oxygen Therapeutics

The MP4 molecule is the basis for Sangart's oxygen therapeutic product platform. The MP4 molecule is created using unique polyethylene glycol conjugation with human hemoglobin and was specifically designed to the optimal molecular size, viscosity, oxygen affinity and diffusion potential to target oxygen delivery to tissues at risk of oxygen deprivation based on experiments with artificial capillaries and in several different animal models. Extensive research and testing demonstrates that this approach optimizes oxygen delivery while minimizing the side effects that plagued earlier generation products.

About Sangart

Sangart, Inc. is a privately held biopharmaceutical company focused on being the global scientific, clinical and commercial leader in oxygen-therapeutic agents, providing innovative products to patients in need. Sangart was founded based on technologies developed during more than two decades of research into the mechanisms of oxygen transport by cell-free hemoglobin solutions at the Letterman Army Institute of Research and University of California at San Diego. The discoveries arising from this research on the effective action of oxygen therapeutics have been patented and published in numerous scientific articles and form the basis for Sangart's technologies.

To learn more about Sangart, please visit the company's website at

    Media Contact:
    Marissa Green
    Edelman Public Relations     Office: 323-202-1463    Cell: 917-345-3684

SOURCE Sangart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sangart, Inc. Announces Key Executive Appointments and Company Restructuring
2. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
3. Cardium Completes $3.5 Million Credit Facility
4. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
5. Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia
6. CIRM Completes Briefing Visit to Stemedica Cell Technologies
7. INVO Bioscience Completes Reverse Merger
8. Particle Sciences Completes Development of First Product Incorporating its Unique Surface Modification System
9. Mach One Corporation Completes Acquisition of Ceres Organic Harvest, Inc.
10. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
11. New Generation Biofuels Completes Construction of Baltimore Facility
Post Your Comments:
(Date:12/1/2015)... 2015  CardioCell LLC, a Stemedica Cell Technologies ... cardiovascular indications, intends to proceed with finalizing a ... from a Heart Failure Advisory Board comprising cardiology ... Board members . In a recent meeting members ... and efficacy data from CardioCell,s on-going chronic heart ...
(Date:12/1/2015)...  Symic, a clinical-stage biotherapeutics company developing multiple compounds ... announced that it has secured $25 million in a ... its lead candidates SB-030 and SB-061. The financing was ... all existing major investors, as well as several new ... by Symic to over $43 million since being founded ...
(Date:12/1/2015)... Texas (PRWEB) , ... December 01, 2015 , ... Matthew ... his new post, VerMilyea will oversee all IVF lab procedures as well ... and fertility preservation. , “We traveled 7,305 miles to Auckland, New Zealand to bring ...
(Date:11/30/2015)... ... 30, 2015 , ... Global Stem Cells Group ... the Santiago Marriott. The Global Stem Cells Group GMP facility is equipped with ... qualified medical researchers and practitioners, experienced in administering stem cell protocols using highly ...
Breaking Biology Technology:
(Date:10/27/2015)... YORK , Oct. 27, 2015 In ... major issues of concern for various industry verticals such ... is due to the growing demand for secure & ... in various ,sectors, such as hacking of bank accounts, ... for electronic equipment such as PC,s, laptops, and smartphones ...
(Date:10/26/2015)... October 26, 2015 ... adds Biometrics Market Shares, ... as well as Emerging Biometrics Technologies: ... to its collection of IT and ... . --> ...
(Date:10/23/2015)... 23, 2015 Research and Markets ( ... Voice Recognition Biometrics Market 2015-2019" report to their ... The global voice recognition biometrics market to grow ... --> --> The report, ... based on an in-depth market analysis with inputs from ...
Breaking Biology News(10 mins):